Tempus AI Target of Unusually Large Options Trading (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) was the target of unusually large options trading activity on Monday. Stock traders bought 88,222 call options on the stock. This represents an increase of 40% compared to the typical daily volume of 63,227 call options.

Tempus AI Trading Down 2.4%

Shares of TEM traded down $1.51 during mid-day trading on Tuesday, reaching $61.96. The company had a trading volume of 12,229,836 shares, compared to its average volume of 6,804,686. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The firm has a fifty day simple moving average of $52.48 and a 200-day simple moving average of $51.90. The stock has a market cap of $10.73 billion and a price-to-earnings ratio of -7.94. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03. The firm had revenue of $255.74 million during the quarter, compared to analysts' expectations of $248.13 million. The firm's quarterly revenue was up 75.4% on a year-over-year basis. On average, sell-side analysts anticipate that Tempus AI will post -6.15 EPS for the current fiscal year.

Insider Buying and Selling

In other Tempus AI news, CFO James William Rogers sold 23,030 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.97, for a total transaction of $1,058,689.10. Following the completion of the transaction, the chief financial officer now owns 164,750 shares of the company's stock, valued at approximately $7,573,557.50. This trade represents a 12.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 562,345 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $50.93, for a total value of $28,640,230.85. Following the completion of the transaction, the chief executive officer now directly owns 9,457,283 shares of the company's stock, valued at approximately $481,659,423.19. This trade represents a 5.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 702,233 shares of company stock worth $36,578,342 in the last three months. Corporate insiders own 27.60% of the company's stock.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cherry Tree Wealth Management LLC acquired a new stake in Tempus AI during the 1st quarter worth approximately $31,000. University of Texas Texas AM Investment Management Co. purchased a new stake in Tempus AI during the first quarter worth approximately $33,000. Operose Advisors LLC acquired a new stake in shares of Tempus AI in the fourth quarter worth $25,000. Bartlett & CO. Wealth Management LLC raised its stake in shares of Tempus AI by 100.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock valued at $39,000 after acquiring an additional 400 shares during the period. Finally, Nemes Rush Group LLC purchased a new position in shares of Tempus AI in the 1st quarter valued at $39,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Piper Sandler boosted their target price on shares of Tempus AI from $55.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, May 15th. BTIG Research initiated coverage on shares of Tempus AI in a research report on Monday, April 21st. They issued a "buy" rating and a $60.00 price objective for the company. TD Cowen reissued a "buy" rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Wolfe Research cut shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "buy" rating and set a $70.00 price target on shares of Tempus AI in a research note on Wednesday, May 7th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $63.42.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.